← brief for 2026-09-03 · Slowing decline

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Trial No results yet Not peer reviewed

Key takeaways

A phase 3 trial is planned for elecoglipron, a new diabetes drug, in adults with type 2 diabetes and reduced kidney function. Everyone in it will already be on dapagliflozin, an SGLT2 inhibitor that is now standard kidney protection, and the new drug will be compared with a dummy pill on top of that. Testing an add-on to current best care is the useful question. No results yet.

Who did this work

Run by AstraZeneca.
Sites: Research Site

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-09-02
https://clinicaltrials.gov/study/NCT07662135